MAPK8 and inflammatory bowel disease: In the present study, we investigated for the first time the therapeutic potential of the JNK-inhibiting peptide XG-102 to counteract the pathological features provoked by TNBS, an acute model of IBD with predominant T helper 1 (Th1)-mediated immune response [38], [39].